Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Open access
Hoyle, Alex P., Ali, Adnan, James, Nicholas D., Cook, Adrian, Parker, Christopher C., de Bono, Johann S., Attard, Gerhardt, Chowdhury, Simon, Cross, William R., Dearnaley, David P., Brawley, Christopher D., Gilson, Clare, Ingleby, Fiona, Gillessen, Silke, Aebersold, Daniel M., Jones, Rob J., Matheson, David, Millman, Robin, Mason, Malcolm D., Ritchie, Alastair W.S., Russell, Martin, Douis, Hassan, Parmar, Mahesh K.B., Sydes, Matthew R., Clarke, Noel W. · 2019 · European Urology

Abstract

BACKGROUND Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE "low-risk" M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). OBJECTIVE Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. DESIGN, SETTING, AND PARTICIPANTS A post hoc subgroup analysis of the 2017 STAMPEDE "abiraterone comparison". Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. RESULTS AND LIMITATIONS A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44-0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17-0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. CONCLUSIONS Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for "risk" or "volume". PATIENT SUMMARY Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2019.08.006

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 203

Metadata

Authors
Hoyle, A. P., Ali, A., James, N. D., Cook, A., Parker, C. C., de Bono, J. S., Attard, G., Chowdhury, S., Cross, W. R., Dearnaley, D. P., Brawley, C. D., Gilson, C., Ingleby, F., Gillessen, S., Aebersold, D. M., Jones, R. J., Matheson, D., Millman, R., Mason, M. D., Ritchie, A. W. S., Russell, M., Douis, H., Parmar, M. K. B., Sydes, M. R., & Clarke, N. W.
Venue
European Urology
Publisher
Elsevier BV
Published
2019-12
Volume
76
Issue
6
Pages
719-728
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2969575782
Cited by
203
References
3
FWCI
18.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2019.08.006
The paper
Hoyle, A. P., Ali, A., James, N. D., Cook, A., Parker, C. C., de Bono, J. S., Attard, G., Chowdhury, S., Cross, W. R., Dearnaley, D. P., Brawley, C. D., Gilson, C., Ingleby, F., Gillessen, S., Aebersold, D. M., Jones, R. J., Matheson, D., Millman, R., Mason, M. D., . . . Clarke, N. W. (2019). Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2019.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.